Skip to main content

Ultra Pure Peptides - Research Use Only - Raw Material Sourced from the USA

Tesamorelin

Tesamorelin

$132.00

SKU: tesa-2mg Categories: , , , , ,

Pickup available at Islip

Usually ready in 24 hours

View store information

Tesamorelin

Islip

Pickup available, usually ready in 24 hours

3 Grant Ave.
Ste. B
Islip NY 11751
United States
+16316770030

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog developed to stimulate endogenous growth hormone (GH) secretion. It is FDA-approved for reducing excess abdominal (visceral) fat in patients with HIV-associated lipodystrophy. By increasing GH and IGF-1 levels, Tesamorelin promotes lipolysis while preserving lean body mass. It is also being investigated for broader metabolic and fat-reduction benefits, including potential applications in non-HIV-related obesity and non-alcoholic fatty liver disease (NAFLD).

Applications
  • FDA-approved treatment for HIV-associated lipodystrophy
  • Reduction of visceral adipose tissue (VAT)
  • Potential fat loss in non-HIV individuals (investigational)
  • Preservation of lean body mass during fat reduction
  • Improvement of lipid profiles
  • Support in reducing liver fat and managing NAFLD
  • Possible protection against age-related muscle loss
Mechanism of Action

GHRH Receptor Activation: Tesamorelin binds to GHRH receptors in the anterior pituitary, stimulating the release of endogenous growth hormone
Increased GH and IGF-1 Secretion: Elevated GH promotes lipolysis, while IGF-1 supports muscle growth and repair
Selective Fat Reduction: Increases fat oxidation, converting fat into energy, particularly abdominal fat

Key Research Studies

1. Visceral Fat Reduction in HIV Lipodystrophy

  • Study focus: Tesamorelin vs placebo over 26 weeks
  • Findings: 15–20% VAT reduction with no significant subcutaneous fat loss
  • Reference: OUP Academic

2. Improved Lipid Profiles

  • Study focus: Blood lipid markers
  • Findings: Lowered triglycerides and improved cholesterol ratios
  • Reference: OUP Academic

3. Liver Fat Reduction (NAFLD relevance)

  • Study focus: Tesamorelin’s effect on hepatic fat in HIV patients
  • Findings: Up to 37% relative reduction in liver fat over 12 months
  • Reference: JAMA Network, The Lancet HIV

4. Sustained VAT Reduction

  • Study focus: 52-week treatment extension
  • Findings: Continued therapy maintained fat loss and improved body image/lipid profiles
  • Reference: NATAP, PubMed

5. Neutral Glucose Metabolism Effects

  • Study focus: Glucose tolerance over time
  • Findings: No clinically significant changes in glucose or insulin markers
  • Reference: OUP Academic, PubMed

Biological Effects and Benefits

Visceral Fat Loss

Significant reduction in abdominal VAT, particularly in HIV patients

Lean Muscle Preservation

Increases IGF-1, helping retain muscle during fat loss

Lipid Profile Improvement

Reduces triglycerides and improves cholesterol ratios

Biological Effects Image

Liver Fat Reduction

May benefit NAFLD and hepatic inflammation

Sustained Effects

Continued treatment maintains body composition changes

Neutral on Glucose Tolerance

Continued treatment maintains body composition changes

Molecular Structure

Molecular Structure
  • Peptide Sequence: His-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Glu-Gln-Gly-Gln-Ser-Ala-Arg-Kys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
  • Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
  • Molecular Weight: 5135.85 g/mol
  • Structure Notes: Long synthetic peptide mimicking endogenous GHRH, enabling stable subcutaneous administration and pituitary activation

Related products